Ensayos clínicos
Los investigadores de BA Psychiatric Research Center tenemos amplia experiencia conduciendo ensayos clínicos de fases III y IV en las siguientes áreas de tratamiento:
Depresión Mayor
Esquizofrenia
Trastorno Esquizoafectivo
Trastorno Bipolar
Trastorno de Pánico

Hemos llevado adelante 16 ensayos clínicos.
Hemos participado en los últimos 10 años en los siguientes ensayos clínicos:
• Protocolo 600 A-GAP AR Wyeth, 1997.
• “Follow Up Program of Patients in treatments on Olanzapine”, Eli Lilly, 1997.
• Protocol CL2-1574-PO-C “Placebo -Fluoxetine -600P -tid -Depression”.
   Institut de Recherches International Servier (IRIS), 1998.
• “Open Study for the efficacy and tolerance of Nefazodone for the treatment of
   Non Psychotic Major Depression”, Laboratorios Rontag, 1998.
• Protocolo EFE XR 37,5 GAP-AR Wyeth, 2001.
• Protocol E1724 Remeron in Panic AKZO NOBEL 2002.
• Protocol F1J-MC-HMAU8 Phase III Duloxetine safety and tolerability in Major
  Depressive Disorder, Ely Lilly, 2002.
• Protocol 060BS399AC Double blind Placebo Control Parallel Group
  Comparison of Venlafaxine Extended Release capsules and Paroxetine in
  outpatients with panic disorder, Sheeba Study, Wyeth Ayerst, 2003.
• Protocol HGU - BC - LRAG Multicentric observational study of patients with
  major depressive disorder, Ely Lilly, 2003.
• Protocol A1281062 Zodiac Study: zyprasidone observational study of cardiac
  outcomes, Pfizer, 2004.
• Protocol BA0105, Alprazolam SL vs. Alprazolam PO in Panic disorder,
  Bagó Laboratories, 2005.
• Protocolo F1D -MC -HGKA, Eli Lilly, 2005.
• Protocol S1543002. “An open-label, flexible-dose, long-term safety and
  efficacy study of Bifeprunox in the treatment of schizophrenia”, Solvay
  Pharmaceuticals Inc., 2005.
• Protocolo F1D -MC -HGKB, Eli Lilly, 2006.
• Protocol SPD417-311, Shire Development Inc., 2006.
• Protocolo DVS SR 402, Wyeth Pharmaceuticals Inc., 2007.